Twenty evaluable patients with primary or secondary neoplastic liver involvement received FUDR (0.2 to 0.3 mg/kg per day) by continuous infusion to the hepatic artery for 14 days, every 4 weeks, through a surgically implanted Infusaid (USA) pump. In addition to FUDR, MMC (15 mg/m2 every 6 to 8 weeks) was given to 14 patients with colorectal cancer and one patient with breast cancer, and ADR, (40 mg/m2 every 4 to 6 weeks) was given to 5 patients with hepatocellular carcinoma. MMC and ADR were given as a bolus injection, through the pump sideport. Radiation therapy to the liver (2,000 rads in fractions of 180 to 200 rads each) was given to eight patients with colorectal carcinoma. In total, the 20 patients received 218 months of treatment and 580 injections. The overall remission rate (complete, partial and minor response) was 55%; one patient with a colorectal carcinoma achieved a CR and seven patients (35%) a PR; three patients (15%) had a MR, and in eight patients (40%) stabilization of disease was observed. Overall median survival was 12 months: 15.5 months for colorectal cancer patients and 7.5 months for patients with hepatocellular carcinoma. Toxicity consisted mainly of chemical hepatitis, mild to severe peptic disease and sclerosing cholangitis. Hematological toxicity was not observed. These data suggest that chemotherapy through the hepatic artery, while still experimental, may be considered for selected patients with tumor confined to the liver.
Devices that are used in the aerospace industry must operate in extreme conditions, so it is important to understand how the properties of materials change under the influence of radiation and low temperatures. Anodic aluminum oxide, due to its mechanical and dielectric properties, is widely used in electronic devices with a high degree of integration. Radiation exposure can lead to degradation of the electrophysical parameters of dielectric films and can also change their chemical composition. The methods for studying the effect of radiation exposure on the dielectric properties of films are shown in this article. The research has been carried out and the results of the influence of α-particles on the dielectric properties of a porous film of anodic aluminum oxide during the influence of low temperature are presented.
Abstract Twelve women who developed breast cancer at the site of old surgical scars in the breast are presented. Six had had former breast biopsies, 3 drainage of breast abscesses, and 3 developed breast cancer in old thoracotomy scars transversing the breast. The combination of trauma as an oncogen and scar tissue as a functional and immunological locus minoris resistentia seems to play a major role in the development of breast cancer in this group of patients. The association of breast cancer, scar, and trauma would not be coincidental. Increased attention drawn to this entity may lead to a rise in the number of cases diagnosed among patients with breast scars after biopsies, abscesses, trauma, or foreign body implantation.
Forty-four patients with metastatic breast cancer were treated with monthly courses of cyclophosphamide, methotrexate and 5-fluorouracil. Complete remission was achieved in five of the 44 patients (11.4%), partial remission in 17 (38.7%) and stabilization in 19 (43.2%). Progression of the disease was seen in three patients (6.7%). Forty patients are still alive and continue to receive chemotherapy. The main side effects were leukopenia, thrombocytopenia, weakness, nausea and vomiting; all were mild and transient, and were treated symptomatically.
10 evaluable patients with metastatic hypernephroma received vinblastine (6 mg/m2, i.v., on days 1 and 8), cyclophosphamide (100 mg/m2, p.o., on days 1–14), and 5-fluorouracil (600 mg/m2, i.v., on days 1 and 8), cycled every 29 days. 7 of the patients also received dexamethasone (16 mg/day, p.o.), shortly before or during chemotherapy, in an attempt to improve their clinical status. No complete or partial responses were seen. 5 patients (50%) remained stable (median duration, 4.5 months; median survival, 6.5 months), and the remaining 5 patients progressed. A subjective response was observed in all stable patients, who also received dexamethasone. The side-effects of VEF chemotherapy were mild: 2/10 patients developed leukopenia (WBC below 3,000), 3/10 patients manifested thrombocytopenia (platelets below 100,000), and 3/10 patients alopecia.
